FCGR2A and inflammatory bowel disease: In IBD patients, mucosal healing is not obtained in 50% of the patients treated with anti-TNF biologics, and therapeutic efficacy is shown to be dependent on the interaction between the Fc region of the anti-TNF IgG and the cellular FcγR.